Latest medical news · page 270

FDA expands Ibrance (palbociclib) approval

Efficacy supplement (new or revised indication). capsule, oral. Sponsor: Pfizer

FDA expands Ibrance (palbociclib) approval

Efficacy supplement (new or revised indication). tablet, oral. Sponsor: Pfizer

FDA approves Subvenite (lamotrigine)

Original new drug approval. suspension, oral. Sponsor: Owp Pharms

Episode 237 -- September 2025 -- Part 1 AFP: American Family Physician

Respiratory syncytial virus vaccination in pregnancy (1:30), vasectomy (3:40), donanemab in Alzheimer disease (7:20), multicancer early detection (12:20), autism spectrum disorder (13:50), and acute pancreatitis (17:10).

What You May Have Missed in 2024: Part 1

Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."

AAFP urges withdrawal of proposed PSLF rule

Episode 65 - All you Need to Know about Traineeships at ECDC

In this episode of ECDC On Air, trainees from the European Centre for Disease Prevention and Control share their unique experiences and insights about the traineeship program. They discuss their backgrounds, daily responsibilities, and provide valuable advice for future trainees. The conversation also covers life in Stockholm, career opportunities post-traineeship, and answers to audience questions, culminating in a rapid-fire round of fun questions. So, meet Arnau Cabruja Amat, Paula Messa Carmona, Dana Alsaialy and Márcia Luís - and find out more about the traineeships at ECDC. Interested in…

FDA expands Koselugo (selumetinib sulfate) approval

Efficacy supplement (new or revised indication). capsule, oral. Sponsor: Astrazeneca

FDA approves Koselugo (selumetinib)

Original new drug approval. capsule, oral. Sponsor: Astrazeneca

NIH releases Alzheimer’s Disease and Related Dementias Research Progress Report and FY27 Professional Judgment Budget

NIH released the FY 2027 Professional Judgment Budget for Alzheimer’s Disease and Related Dementias and the NIH Scientific Progress Report.

FDA expands Skyrizi (risankizumab-rzaa) approval

Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Abbvie Inc

FDA expands Skyrizi (risankizumab-rzaa) approval

Efficacy supplement (new or revised indication). injectable, intravenous. Sponsor: Abbvie Inc

Level 2 - Yellow Fever in Colombia

An increased number of cases of yellow fever have been reported in Colombia.

Fibrillation - When Ablation is the Way to Go

Dr. Centor discusses the role of ablation in the management of patients with atrial fibrillation with Dr. Peter Zimetbaum.

Episode 236 -- August 2025 -- Part 2 AFP: American Family Physician

Contraception (1:30), delayed pushing in labor (6:10), bacterial vaginosis (8:50), outpatient care of the premature infant (11:10), nocturnal leg cramps (17:30), and AFP Clinical Answers (19:20).

FDA approves Leqembi Iqlik (lecanemab-irmb)

Original biologic license approval. injectable, subcutaneous. Sponsor: Eisai Inc

FDA approves Camcevi Etm (leuprolide mesylate)

Original new drug approval. emulsion, subcutaneous. Sponsor: Accord

Episode 235 - August 2025 - Part 1 AFP: American Family Physician

Heart failure with reduced ejection fraction (1:30), lower gastrointestinal bleeding (5:10), venous leg ulcers (7:10), nonopioid pharmacologic management of chronic pain (10:30), resuscitation in burns (15:20), and breast ductal carcinoma in situ (17:10).

Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes

Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.

FDA expands Vyepti (eptinezumab-jjmr) approval

Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Lundbeck Seattle Biopharmaceuticals, Inc.

FDA expands Wegovy (semaglutide) approval

Efficacy supplement (new or revised indication). solution, subcutaneous. Sponsor: Novo

FDA approves Hernexeos (zongertinib)

Original new drug approval. tablet, oral. Sponsor: Boehringer Ingelheim

FDA expands Ajovy (fremanezumab-vfrm) approval

Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Teva Pharms Usa

Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control is Inadequate on Dulaglutide

Dr. Centor discusses outcomes in patients with inadequately controlled type 2 diabetes when the dulaglutide dose is escalated versus switching to tirzepatide.